Pilgrim Partners Asia Pte Ltd Makes New $2.49 Million Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 40,000 shares of the company’s stock, valued at approximately $2,494,000. TransMedics Group accounts for about 2.2% of Pilgrim Partners Asia Pte Ltd’s investment portfolio, making the stock its 12th largest position. Pilgrim Partners Asia Pte Ltd owned 0.12% of TransMedics Group at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TMDX. Norges Bank bought a new stake in TransMedics Group in the 4th quarter worth approximately $22,861,000. Emerald Advisers LLC increased its holdings in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock worth $23,176,000 after buying an additional 220,804 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after buying an additional 146,115 shares in the last quarter. State of Michigan Retirement System bought a new position in shares of TransMedics Group in the 4th quarter valued at about $6,734,000. Finally, Raymond James Financial Inc. purchased a new position in TransMedics Group in the fourth quarter worth about $3,845,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 4.6 %

TransMedics Group stock opened at $67.67 on Friday. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. The stock has a 50-day moving average of $70.07 and a two-hundred day moving average of $85.74.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Piper Sandler lowered their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Robert W. Baird lowered their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.